Vitality Watch

Dossier pubmed preclinical 01-nov-2026
Animal model, organoid, or cell-culture result — not yet human

Klotho Deficiency Impairs Distal Potassium Homeostasis Through mTORC1-Dependent Suppression of ROMK.

Key claim: Klotho deficiency impairs distal renal potassium handling through mTORC1-dependent suppression of the ROMK channel, a defect reversible by rapamycin or Klotho supplementation.

Abstract

AIM: Hyperkalemia is prevalent in the elderly, and underlying molecular mechanisms remain incompletely understood. We hypothesized that Klotho deficiency, a feature of aging, impairs renal potassium homeostasis and contributes to hyperkalemia. METHODS: Klotho heterozygous knockout (KLhet) mice, characterized by reduced Klotho levels, were used to investigate determinants of potassium handling, including renal outer medullary potassium channel (ROMK)1, the epithelial sodium channel (ENaC), which provides the driving force for ROMK-mediated potassium secretion, and plasma aldosterone concentration (PAC). RESULTS: KLhet mice developed hyperkalemia with reduced urinary potassium excretion, accompanied by activation of renal mechanistic target of rapamycin complex 1 (mTORC1) signaling, indicated by increased phosphorylated S6, and decreased ROMK1 abundance in the plasma membrane fraction. Adrenal expression of aldosterone synthase Cyp11b2 and PAC were elevated, and ENaC activity was enhanced, as evidenced by increased cleavage of α- and γ-ENaC subunits, partially compensating for impaired potassium excretion. Pharmacological ENaC inhibition with amiloride precipitated severe hyperkalemia in KLhet mice. In contrast, treatment with the mTORC1 inhibitor rapamycin or Klotho supplementation suppressed renal mTORC1 signaling, restored plasma membrane ROMK1 abundance, increased urinary potassium excretion, and normalized serum potassium levels, with reduced Cyp11b2 expression. CONCLUSION: Klotho deficiency impairs renal potassium handling through mTORC1-dependent downregulation of ROMK, with compensatory hyperaldosteronism and ENaC activation. These findings highlight an important role of the Klotho-mTORC1 axis in distal potassium homeostasis and its potential as a therapeutic target for Klotho deficiency-associated hyperkalemia.

Why this matters

[animal-model] This finding extends the Klotho–mTORC1 causal picture to distal renal potassium handling, with rescue experiments supporting a reversible channel-regulatory defect in mice. [animal-model] The rapamycin and Klotho-replacement results establish a preclinical intervention link, not evidence that either approach safely corrects age-related electrolyte dysregulation in humans.

Source

Link

Briefing card

Klotho Deficiency Impairs Distal Potassium Homeostasis Through mTORC1-Dependent Suppression of ROMK.
Stage: preclinical · pubmed · 01-nov-2026

If you take rapamycin, this mouse study does not establish that it improves your potassium regulation.

Klotho deficiency impairs distal renal potassium handling through mTORC1-dependent suppression of the ROMK channel, a defect reversible by rapamycin or Klotho supplementation.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1111/apha.70325

build build 880 · 2bcef25 · 2026-11-18